Amphastar Pharmaceuticals, Inc.
AMPH
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.0B
$23.18
▼ -2.77%
P/E
13.56
Mkt Cap
$1.0B
52-Wk Range
$16.65–$29.52
52-Week Range
$16.65 - $29.52
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 20.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Vertical integration with in-house API manufacturing reducing costs and supply chain risks
- Specialized focus on niche emergency and critical care medications with limited generic competition
- Established relationships with hospitals, healthcare facilities, and emergency care providers
- Portfolio of both generic and proprietary products providing pricing power and differentiation
- Manufacturing capabilities across multiple dosage forms (injectable, inhalation, intranasal)
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Increasing opioid crisis awareness driving demand for Naloxone and emergency medications
Value
Undervalued - trading well below Large Cap Pharma peers
Momentum
Strong
+19.6% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying AMPH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.91 vs $0.62 consensus (+46.8% surprise). Revenue of $183.9M vs $179.9M expected (+2.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+46.8%
Revenue trend · last 8Q
—
+5%
-1%
-4%
+2%
-2%
+0%
+5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$188.8M
$186.5M
$170.5M
$174.4M
$191.8M
$183.1M
$171.2M
$183.9M
Margins · last 8Q
Gross
50.8%
Operating
21.6%
Profit
16.5%
Wall Street consensus
6 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
83%
Sell
17%
Median Price Target
—
Latest: Bank of America · Jun 29, 2026
vs Industry
How AMPH stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related